Mounjaro and Obesity/Metabolism?

By Gwynne Sullivan, Amy Nowacoski · last reviewed May 9, 2026

Adapted from the Mounjaro for Diabetes FAQ with permission from the contributing authors.

The SURMOUNT-3 trial article (linked elsewhere in this document!) has much information on weight loss t results and reduction in waist circumference, with great visual aids illustrating findings on this and other topics.

Clinical trials are ongoing to uncover more. One is not even testing doses less than the 10mg.

Can New Weight-Loss Drugs Really Treat Obesity? Yale Medicine, June 2022 https://www.yalemedicine.org/news/new-medications-treat-obesity

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients TCT MD, June 2022 https://www.tctmd.com/news/surmount-1-tirzepatide-drastically-reduces-weight-obese-patients

Anti-obesity drug discovery: advances and challenges Nature reviews Drug Discovery, 2022 https://www.nature.com/articles/s41573-021-00337-8?fbclid=IwAR0fR2NNsIyDI5H6wYuFS8WBP0yO6f5aLUd27avhMauKd7hQ_vpcrSKJl1Q

Efficacy of GLP-1 Agonists for Weight Loss in Adults Without Diabetes Clinical Advisor June, 2022 https://www.clinicaladvisor.com/home/topics/obesity-information-center/glp-1-agonists-weight-loss-adults-without-diabetes-liraglutide-semaglutide/

Glucagon, GLP-1 and Thermogenesis Int J Mol Sci. 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678955/

The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome Life (Basel). 2022 August https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410036/